Simple Summary Prostate cancer affects men of all racial and ethnic groups and leads to
higher rates of mortality in those belonging to a lower socioeconomic status due to late …

CONTEXT: Prostate cancer (PCa) remains an increasingly common malignancy worldwide.
The optimal management of clinically localized, early-stage disease remains unknown, and …

Purpose We assessed the outcome of a watchful-waiting protocol with selective delayed
intervention by using clinical prostate-specific antigen (PSA), or histologic progression as …

The definition of clinically significant prostate cancer is a dynamic process that was initiated
many decades ago, when there was already evidence that a great proportion of patients with …

Background After 11 years of follow-up, the European Randomized Study of Screening for
Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men …

Purpose We assessed outcomes of men with prostate cancer enrolled in active surveillance.
Patients and Methods Since 1995, a total of 769 men diagnosed with prostate cancer have …

Purpose: Targeted biopsy of lesions identified on magnetic resonance imaging may
enhance the detection of clinically relevant prostate cancers. We evaluated prostate cancer …

Methods: A literature search of MEDLINE, EMBASE, the Cochrane library, guideline
databases and relevant meeting proceedings was performed and a systematic review of …

Widespread prostate-specific antigen (PSA)–based screening and aggressive treatment of
prostate cancer have reduced mortality rates substantially, but both remain controversial in …

Background Active surveillance (AS) aims to allow men with favourable-risk, localised
prostate cancer to avoid unnecessary treatment. Objective To describe the clinical outcomes …